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Abstract
Heart failure (HF) is a manifestation of aberrant vascular responses and remains a public 
health concern with a worldwide prevalence of around 23 million and a 5-year mortality nu-
merically equivalent to many cancers. Over the last two decades, mortality from HF reached  
a plateau with current pharmaceutical agents and mechanical cardiac support. In the last several 
years, various “novel” pharmaceutical agents have been tested in clinical trials and ultimately 
met with disappointment, showing only incremental benefit in the treatment of HF. Designing 
a HF drug with enhanced efficacy over existing agents seemed like a Sisyphean task. Yet again, 
pharmaceutical chemists have demonstrated their prowess in lateral thinking by developing  
a vasoactive agent which is a co-crystallized compound of valsartan and sacubitril in a one-to- 
-one molar ratio; the former molecule belongs to a family of agents that are the current standard 
of care for HF and the latter molecule is a novel agent which inhibits neprilysin — a neutral 
endopeptidase found in human plasma which alters neurohumoral responses. In July of 2015, 
a drug which is a combination of valsartan and sacubitril was formally licensed by the United 
States Food and Drug Administration for the treatment of HF. This review describes the evolu-
tion of HF medications focusing on rational drug design with the first HF medication, the beta- 
-adrenergic receptor antagonist. We then discuss the biochemical and physiological properties 
of sacubitril/valsartan which likely lead to its dramatic ability to ameliorate HF mortality. 
(Cardiol J 2016; 23, 6: 591–598)
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Introduction
Heart failure (HF) is a complex clinical syndrome 
driven by inadequate circulatory blood flow for the 
metabolic demands of vital organs such as the brain 
and kidneys. Effectively, the heart pumping function 
begins to fail, hence the term, HF. In the western 
world, the leading cause of HF overwhelmingly 
is the result of diseased coronary arteries which 
supply the heart muscle with blood. This is termed 
ischemic cardiomyopathy [1]. Other causes of ac-
quired HF include: uncontrolled high blood pressure, 
viral infections, autoimmune disease, drug toxicity, 
metabolic derangements, as well as rare inherited 
genetic defects — all grouped under the umbrella of 
non-ischemic cardiomyopathy [2].
Heart failure may manifest physiologically as 
an inefficient ability of the heart muscle to contract 
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(systolic dysfunction) or an inefficient ability of the 
heart muscle to relax (diastolic dysfunction, also 
referred to as heart failure with preserved ejection 
fraction [HFpEF]) [3]. HF manifests as a variety of 
symptoms including: fatigue, shortness of breath, 
chest pain, abdominal pain, abdominal distension, 
weight gain, and swelling of the lower extremities. 
When HF is appropriately treated, patients are 
stated to have compensated HF and, when acutely 
ill and very symptomatic, patients are stated to 
have decompensated HF [4]. Medications used to 
treat HF symptoms have evolved over the last few 
decades. Initial therapies focused on downstream 
targets such as renal tubules (i.e. diuretics) and 
myocardial contractility (i.e. inotropes) which 
enabled symptom relief, but offered no mortality 
benefit. Contemporary pharmacologic therapy has 
moved upstream in the cellular signal transduction 
pathway, targeting neurohormonal modulation in-
volving angiotensin converting enzyme inhibitors 
(ACEIs), angiotensin receptor blockers (ARBs), 
beta-blockers and mineralocorticoid receptor an-
tagonists (MRAs) which has resulted in summative 
mortality benefit [5]. In addition, percutaneous 
devices including implantable defibrillators, dual 
ventricular pacing via ‘cardiac resynchronization 
therapy’, and surgically implanted ventricular as-
sist devices have further extended the life of HF 
patients [6–10]. Over the last 5 years, cardiac me-
chanical circulatory support devices have improved 
and grown from acute support/bridge therapies 
to destination therapies which overshadowed 
pharmacological management of HF. Mechanical 
devices are invasive, expensive, and create addi-
tional complications in the management of patients 
with an already complicated disease such as HF. 
Until last year, it was felt that no further refine-
ments could be made upon existing pharmacologic 
agents to improve patient outcomes. In as much 
as the beta-blockers were discovered by the late 
Scottish physician, pharmacologist, and Nobel 
Laureate Sir James Whyte [11], subsequent years 
saw the development of ACEIs, ARB, MRAs, until 
this year when pharmaceutical chemists once again 
demonstrated their skill in drug formulation to 
create the perfect compound of two existing drugs 
which surpass the current standard of medical care 
for patients with HF.
What works: Pharmacological successes  
in heart failure treatment
Basic laboratory scientists have struggled 
for years to improve upon HF medications in part 
because it was believed that HF is a disease that 
can be best controlled by altering cellular signaling 
pathways most responsible for the pathophysiologi-
cal events in HF. HF involves excessive activation 
of the sympathetic nervous system, the synthesis 
and release of hormonal agents, and activation of 
aberrant cellular signal transduction pathways 
inside myocardial cells and in surrounding cells 
which comprise heart tissue [12–15]. Much of the 
initial effort into understanding and treating HF 
was directed toward the beta-adrenergic receptor 
signaling pathway and the angiotensin receptor 
signaling pathways — both of which are exces-
sively activated in HF. 
Without question, the beta-adrenergic recep-
tor antagonists were an extraordinary medical 
discovery and truly were the initial revolutionary 
treatment of HF. It is fair to say that the success 
of discovering and implementing beta adrenergic 
receptor antagonists was attributed to Sir James 
Whyte Black and his team of chemists who made 
a scientific observation in the early 1960s that 
dichloroisoproterenol (DCI) appeared to function 
as a beta-adrenergic receptor antagonist. They 
then realized that chemical modifications of this 
molecule would be required for it to have efficacy 
on living tissue. The structural changes to DCI 
produced the candidate pharmaceutical agent 
pronethalol, which would become the foundation 
of the family of beta-adrenergic receptor antago-
nists that would be later refined for the treatment 
of HF [16, 17]. This lesson clearly highlights the 
need to integrate scientific endeavors between 
pharmaceutical and synthetic organic chemists who 
design and synthesize drugs with pharmacologists 
who study the effect of medications on tissue, and 
clinicians who will eventually prescribe the medi-
cations. It is somewhat fortuitous and potentially 
revealing that Dr. Black — while initially trained 
in clinical medicine — devoted his entire career 
to pharmaceutical chemistry and so was able to 
simultaneously fulfill the role of both scientist and 
physician. Drug discovery and refinement in our 
highly regulated society generally does not func-
tion this way today. 
While stimulation of the beta1-adrenergic re-
ceptor is responsible for the inotropic (contractile) 
function of cardiac myocytes, it initially seemed 
counterintuitive that beta1-receptor antagonists 
such as bisoprolol, metoprolol, and carvedilol 
could improve HF symptoms and prolong life in 
patients with HF [1, 16, 18–20]. Cardiac myocyte 
toxicity through excessive beta1-stimulation in 
fact involves a cascade of intracellular biochemical 
events including intracellular calcium overload, 
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programmed cell death (apoptosis), and remodeling 
of the extracellular matrix [20, 21]. It became clear 
that biochemical events responsible for inotropic 
incompetence — in part through excessive sym-
pathetic nervous system activation — involve 
covalent modification of the beta1-adrenergic 
receptor through phosphorylation by intracellular 
protein kinases, subsequent beta1 desensitization 
and down-regulation by intracellular trafficking 
[9, 15, 17, 22]. It is unclear why only a few medications 
among the beta-adrenergic receptor antagonists 
have mortality benefit in HF but, nonetheless, 
beta-blockers partly reverse sympathetic nerv-
ous system-induced receptor internalization by 
recycling some beta1 receptors to the cell surface 
and restoring inotropic competence. Thus, by syn-
thesizing antagonists against cell surface receptors 
and inhibitors of enzymes involved in post-receptor 
signaling mediators including second messengers, 
patients with HF began to live longer. Upon initiat-
ing beta1-adrenergic receptor antagonists in the 
early treatment of HF, it may not have been ap-
preciated that beta1-adrenergic receptors in the 
kidney promote the release of the hormone renin, 
which further augments the hormonal aberrancies 
of HF [23]. As such, beta1-adrenergic antagonists 
have pleotropic effects in the management of HF.
The 1980s and 1990s harbored in clinical 
evidence for the treatment of chronic systolic 
HF involving antagonism of the renin–angioten-
sin–aldosterone system (RAAS) to counteract 
the maladaptive neurohormonal changes. In brief, 
renin is a circulating proteolytic enzyme produced 
by the kidney which converts the plasma peptide 
angiotensinogen to angiotensin I. Angiotensin I is 
converted to angiotensin II (Ang II) by the enzyme 
ACE which lines the innermost layer of the blood 
vessel wall. Ang II when produced in excess in 
patients with failing hearts promotes narrowing 
of blood vessels, sodium retention directly, and by 
secretion of aldosterone from the kidney, sodium 
retention indirectly and plasma volume expan-
sion (Fig. 1). Over the years, multiple attempts 
have been made to interfere with the various 
components of the RAAS by employing enzyme 
inhibitors against the hormone renin and ACE and 
competitive pharmacological antagonists against 
the Ang II and aldosterone receptors [1, 24]. Of 
these various agents, only renin inhibitors were 
plagued by poor bioavailability when taken orally 
and failed to show marked clinical efficacy for HF 
management, ultimately gaining approval by the 
United States Food and Drug Administration for 
hypertension management [21]. Nonetheless, 
a valiant effort persists today to assess the efficacy 
of the renin inhibitor alisikiren in a highly selec-
tive multinational HF study ATMOSPHERE [25]. 
The pivotal CONSENSUS group study and the 
SOLVD trial indicated enalapril offered significant 
mortality benefit as compared to placebo [26, 27]. 
The mortality benefit offered by ACEI therapy was 
confirmed when examining other medications in 
the class, such as captopril and ramipril [28, 29]. 
Early data suggested angiotensin receptor blockade 
offered similar mortality benefit as ACEI and was 
confirmed in the larger study, ELITE II, comparing 
losartan with captopril [30, 31]. Candesartan stood 
alone to improve mortality as compared to placebo 
and solidified ARBs in systolic HF as demonstrated 
by the CHARM study, while the VALIANT study 
showed clinical efficacy by blocking ARBs with val-
sartan [32, 33]. Aldosterone receptor antagonists 
spironolactone and eplerenone have clear efficacy 
and mortality benefit in patients with systolic HF 
in the RALES and EPHESUS studies, respectively, 
and remain the standard of adjunctive medical 
therapy for systolic HF management today.
After around a decade of ‘false starts’, a new 
class of medication for HF management emerged 
around 2010 in the medication ivabradine. Based 
on the principle that systolic HF results from 
excessive sympathetic activation, and this trig-
gers pathological intracellular signal transduction 
pathways [15, 34–37], we recently saw the imple-
mentation of ivabradine in well-controlled clinical 
studies [38, 39]. Ivabradine was the first class of 
HF medications which directly blocks ion channels 
in electrical nodal tissue which generate the action 
potential, thus limiting cardiac pacemaker activity 
and also the increase in heart rate common to ex-
cessive sympathetic activation in HF. It therefore 
stands to reason that the most efficacious agents 
used to treat the signaling aberrancies in HF, such 
as the beta-blockers, ACEIs and ARBs, would 
eventually reach a glass ceiling, and attempts to de-
velop more efficacious drugs against these targets 
were met by incremental clinical benefits against 
HF which was and still is a major individual and 
societal burden. With the exception of ivabradine’s 
recent promising data, it was clear to physicians, 
basic scientists, and pharmaceutical chemists that 
the specter of HF casts a very long shadow and 
something different was needed.
What did not work: Pharmacological  
disappointments in heart failure treatment
The pathophysiology of HF culminates in 
myocardial cell stretch through excessive volume 
www.cardiologyjournal.org 593
Erik H. Howell, Scott J. Cameron, Sacubitril/valsartan regulates vascular responses in heart failure
and pressure and this promotes the synthesis, stor-
age, and granular release of vasoactive peptides 
such as atrial natriuretic peptide (ANP) and brain 
natriuretic peptide (BNP) from cardiac myocytes 
[40–42]. ANP and BNP are among the neurohu-
moral mediators which serve as markers of HF 
severity, but also may alleviate some of the mala-
daptive physiological processes in decompensated 
HF. ANP and BNP, as their names suggest, promote 
natriuresis and therefore osmosis in kidney tubules 
of patients in HF, with a net diuretic response. 
These effects restore fluid homeostasis which 
becomes dysregulated in patients with HF. Indeed, 
when the mechanical function of the heart is com-
promised in HF, blood vessel capillary hydrostatic 
pressures increases, and fluid extravasation occurs 
according to the Starling equation [43]. Diuretic 
medications promote fluid excretion through the 
kidneys and treat the effects of a dysregulated, 
failing heart. The use of diuretic medications has 
always been — and therefore always will be — 
a natural component of the drug armamentarium 
Figure 1. Physiological effects of neprilysin and angiotensin receptor antagonism in vivo; abbreviations — see text.
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for treating decompensated HF. Diuretics, however, 
do not address the underlying pathophysiological 
causes of HF because their perpetual use serves 
only to augment the RAAS which is the aberrant 
hormonal cascade of HF [44].
Effectively, the synthesis and secretion of 
endogenous natriuretic peptide agents appears to 
be a protective mechanism to counteract adverse 
pathophysiological processes in HF. The natriu-
retic and diuretic effect of ANP and BNP also 
opposes the dysregulated activity of the RAAS, 
which are common in etiology of decompensated 
HF. As peptide signaling mediators, ANP and 
BNP also stimulate G-protein coupled receptors 
(GPCRs) on vascular smooth muscle cells which 
promote the synthesis of the second messenger 
cyclic guanosine monophosphate (cGMP) which 
decrease vascular smooth muscle tone [15, 45, 46]. 
When vascular smooth tone decreases, peripheral 
vascular resistance decreases, and the net effect 
is decreased capillary hydrostatic pressure, and 
improved cardiac output by decreasing afterload 
on the heart muscle.
For the physiological reasons noted above, it 
would seem intuitive that supplementing ANP or 
BNP intravenously should promote natriuresis, 
diuresis, and improve cardiac output in patients with 
HF. BNP supplementation did indeed reverse some 
subjective symptoms as well as some of the aberrant 
neurohumoral and hemodynamic derangements in 
patients with HF, but a well-controlled clinical trial 
failed to demonstrate mortality benefit in these pa-
tients compared to placebo and the drug is no longer 
endorsed for clinical use in patients with HF [46, 47].
What we always hoped for: A pharmaceutical 
breakthrough in heart failure treatment 
Neprilysin is a membrane-bound metallo-
endopeptidase with a coordinated zinc ion within 
the catalytic site. Neprilysin is fairly ubiquitous, 
with expression in cardiac myocytes, endothelial 
cells, and vascular smooth muscle cells. Neprilysin 
is responsible for the inactivation and degradation 
of the natriuretic peptides as well as other circulat-
ing vasodilating mediators including substance P 
and bradykinin (Fig. 1) [48, 49]. 
Accordingly, it has been shown that inhibitors 
of metallo-endopeptidase promote a natriuretic as 
well as a diuretic effect, and they decrease blood 
pressure by promoting relaxation of resistance 
arterioles [50]. In some respects, it may be per-
ceived that neprilysin inhibition is not dissimilar 
to natriuretic peptide supplementation and so may 
be as ineffective as the clinical studies which in-
vestigated the effect of natriuretic peptide infusion 
on HF morbidity and mortality. The OVERTURE 
study compared the neprilysin inhibitor omapatrilat 
to the ACEI enalapril in treating HF, finding only 
marginally improved clinically efficacy with oma-
patrilat [51], and thus neprilysin as a drug target 
for HF retreated into obscurity for over a decade. 
The much vaunted PARADIGM-HF trial deliv-
ered everything that physicians and scientists long 
hoped for: a well-controlled, high quality clinical 
investigation showing a novel pharmaceutical agent 
which significantly improved upon the current 
standard of care for HF [52, 53]. The ingenuity 
behind sacubitril/valsartan lies in the decision to 
administer a compound of a neprilysin inhibitor as 
a pro-drug (sacubatril) with an angiotensin recep-
tor antagonist (valsartan). This combination was 
proposed to maximize the protective effects of 
endogenous natriuretic and vasodilating mediators 
whilst minimizing the deleterious effects of an-
giotensin II accumulation. PARADIGM-HF tested 
sacubitril/valsartan, which is a robust inhibitor of 
RAAS, demonstrating an overwhelming mortality 
benefit comparing sacubitril/valsartan to the ACEI 
enalapril that the study was stopped early at the 
recommendation of the clinical trial data and safety 
monitoring board.
In addition, sacubitril/valsartan also reduced 
hospitalization for HF in one fifth of the patient 
population studied compared to enalapril [52]. An 
important consideration is that endogenous nepri-
lysin not only degrades natriuretic and vasodilating 
molecules, but also Ang II which drives dysregu-
lated hemodynamics and myocardial remodeling in 
HF [54, 55]. After much thought, clinical pharma-
cologists proposed that the once daily dosing of the 
neprilysin inhibitor which was attempted in past 
clinical trials may be a reason behind its marginal 
benefit over ACEI in prior clinical studies [47, 
56], and they began working with pharmaceuti-
cal chemists to solve two problems: 1. Improve 
the bioavailability of a drug which functions as 
a neprilysin inhibitor; 2. Block the hemodynamic 
and neurohumoral effects of increased circulating 
Ang II concentration which is common to both the 
pathophysiology of HF and the use of a neprilysin 
inhibitor. Sacubitril/valsartan is a 1:1 molar ratio 
of the ARB valsartan and the neprilysin inhibitor 
sacubitril. Sacubatril is an inactive pro-drug (AHU-
377) which is converted to an active neprilysin 
inhibitor (LBQ657) through esterase-mediated 
de-ethylation following oral administration [57, 
58]. The physiological effects of combined nepri-
lysin with angiotensin receptor antagonism which 
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generally promote vasodilation, natriuresis, and 
decrease blood pressure, cardiac workload, and 
adverse remodeling of the cardiac interstitium are 
shown in schematic form (Fig. 1). When consid-
ering any new therapeutic agent, a fatal mistake 
and one that may challenge the longevity of any 
new therapeutic agent is when clinicians work in 
parallel to rather than in unison with pharmaceuti-
cal chemists when the stage of drug formulation 
is reached. Appropriate care should be directed 
toward the chemistry of drug synthesis and po-
tential drug modification by metabolic enzymes 
in the body. In the case of sacubitril/valsartan, 
subsequent pharmacokinetic studies confirmed 
that synthesizing valsartan as an anionic salt of 
molecular weight 957.99 and empirical formula: 
C48H55N6O8Na32.5H2O in sacubitril/valsartan was 
an excellent decision which increased valsartan 
bioavailability on average by 50% compared to 
ingestion of equimolar and equivalent doses of 
valsartan and sacubitril as separate drugs [56, 
58]. When administered as the co-crystalized 
compound sacubitril/valsartan, the individual 
agents valsartan and LBQ657 dissociate, and 
have a blood elimination half-life of around 11 h, 
reaching a plasma steady state concentration in 
3 days. This makes sacubitril/valsartan suitable 
for twice daily dosing [59–61]. Pharmaceutical 
chemist and clinical pharmacologists have highly 
developed skills in drug synthesis and optimiz-
ing the pharmacodynamic effect of a drug, while 
physicians are uniquely qualified to evaluate the 
gaps in drug efficacy. Similar to the success of the 
beta-adrenergic antagonists, the success of sacu-
bitril/valsartan, therefore, is a clear reminder to 
both the scientific and the medical community that 
pharmaceutical chemists and physicians working 
together accomplish greater things for patient care 
than working separately.
Neprilysin inhibition with an angiotensin 
receptor antagonist: Cautionary remarks
Based on the profound effect sacubitril/vals-
artan has on cardiac afterload (Fig. 1), a real con-
cern is the propensity for this combined therapy 
to precipitate symptomatic hypotension, as was 
described in the PARADIGM-HF Trial [52] and 
echoed with similar prevalence in a past clinical 
study of a neprilysin inhibitor with an ACEI [62]. 
This is especially important given that patients 
with chronic systolic HF generally also have 
dysregulated sympathetic tone as well as impair-
ment in renal blood flow, and raises the issues of 
unpredictability in determining appropriate patient 
dosing schedules.
Neprilysin in an important enzyme in the 
homeostasis of and, in particular, the degradation 
of amyloid-beta-peptide in the brain and the eye 
— a peptide for which excessive accumulation and 
aberrant deposition is well known in the etiology 
of Alzheimer’s disease as well as certain forms of 
macular degeneration [63, 64]. Accumulation of 
amyloid peptide closely mimics the phenotype of 
Alzheimer’s disease in a murine model [65] and, in 
fact, an active area of investigation in the treatment 
of Alzheimer’s disease is to employ therapeutic 
agents to augment neprilysin activity [59]. This 
raises the very real concern that in our quest to 
find the next ‘silver bullet’ for the treatment of HF, 
we may inadvertently be predisposing patients to 
neurological and ophthalmic dysfunction from the 
off-target effects that are inevitable for any thera-
peutic agent, and occasionally underappreciated 
until the stage of post-marketing surveillance of the 
drug by the Food and Drug Administration Adverse 
Event Reporting System. Further research into the 
effect of neprilysin inhibition in the development of 
neurodegenerative disease is therefore warranted.
Future directions in the pharmacological 
management of heart failure
A patient population that deserves special 
attention is those patients with HFpEF. Dias-
tolic heart dysfunction or ‘heart stiffening’ is an 
expected expression of the aging heart and, as 
we become more skilled at treating disease and 
more sophisticated in diagnostic imaging, there 
is a somewhat misleading trend of an increased 
prevalence of HFpEF [66]. While HFpEF as 
a clinical disorder can be a secondary manifestation 
of myocardial hypertrophic and infiltrative diseases 
[60, 61], the biochemical and cellular mechanisms 
leading to the disorder are poorly defined, though 
interstitial cell fibrosis is believed to be a com-
mon endpoint [67]. It has been proposed that 
HFpEF may be a consequence of microvascular 
dysfunction and subsequent myocardial fibrosis 
which evades conventional myocardial imaging 
of epicardial coronary vessels [68]. Others have 
shown that proliferation of cardiac fibroblast in the 
extracellular matrix and deposition of collagen is 
commonplace in the heart of patients with HFpEF 
[69, 70]. Various sophisticated laboratory inves-
tigations have shown the presence of the Ang II 
receptor on fibroblasts and, when stimulated, 
collagen deposition into the extracellular matrix 
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occurs [71–73]. The involvement of the RAAS is 
important for remodeling of the extracellular ma-
trix, and this in turn affects the ability of the heart 
muscle to relax and is therefore a prerequisite for 
HFpEF [74]. With this fact in mind, the failure of 
an aldosterone receptor antagonist in the TOPCAT 
study to meet its primary endpoint for clinical ef-
ficacy in patients with HFpEF was surprising [75]. 
Nonetheless, hospitalization for HF was less in 
the drug treatment arm. Moreover, by subgroup 
analysis, the primary outcome for drug treatment 
was actually met in patients from the Americas but 
not Eastern Europe. While a regional difference in 
drug effect was hypothesized, another interpreta-
tion is that pharmacological blockade of the RAAS 
appears to be a necessary but insufficient step in 
the treatment of HFpEF. Neprilysin inhibitors were 
also shown to prevent myocardial hypertrophy but 
not fibrosis in animal models of HF [61, 76, 77]. 
We know that neprilysin inhibition can attenuate 
myocardial remodeling in humans. The prospect 
that sacubitril/valsartan may also have efficacy in 
HFpEF is therefore also being tested, with smaller 
scale clinical trials already showing efficacy [28]. 
Conclusions
Sacubitril/valsartan may indeed self-declare as 
a silver bullet in the treatment of systolic as well 
as diastolic HF. Clinicians do not always possess 
the research armamentarium required to evaluate 
and synthesize new medications, but they are in 
the unique position to evaluate gaps in current 
medical therapy and to ask important questions. 
Pharmacologists and pharmaceutical chemists do 
not always appreciate the nuances of clinical care, 
but they are highly skilled in synthesizing and 
evaluating the effect of drugs in living organisms. 
Since sacubitril/valsartan is essentially a cleverly 
formulated version of two medications that have 
been available for over a decade, the remarkable 
success of sacubitril/valsartan in ameliorating HF 
serves as a signpost to remind the medical commu-
nity and the pharmaceutical industry that working 
together maximizes the academic impact of any 
endeavor and, in fact, it is our moral obligation for 
effective patient care.
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